Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ellen Matzkin"'
Autor:
Ellen Matzkin, Jose R. Zanchetta, Pierre D. Delmas, John F. Beary, Claude-Laurent Benhamou, Christian Roux, Steven Boonen, Rachelle Eusebio, Z. Man, Artur J. Racewicz, Michael R. McClung, David Ernest Burgio
Publikováno v:
Osteoporosis International
Summary: This study showed that risedronate 150-mg once a month provides similar efficacy and safety at 2 years compared with risedronate 5-mg daily for the treatment of postmenopausal osteoporosis. This adds to the range of risedronate dosing option
Autor:
Lynn M. Darbie, Jacques P. Brown, Artur J. Racewicz, Ellen Matzkin, John F. Beary, David Ernest Burgio, Louis-Georges Ste-Marie
Publikováno v:
Clinical Therapeutics. 31:272-285
Risedronate 5 mg/d is approved by the US Food and Drug Administration for the treatment and prevention of postmenopausal osteoporosis. Once-monthly dosing options might increase treatment compliance and persistence.The aim of this study was to compar
Autor:
Xuedong Chi, Paul P. Tak, Clarissa E. Vergunst, Danielle M. Gerlag, Lisa L. von Moltke, Michael Karol, Ellen Matzkin, Tim Wyant, T. Leach
Publikováno v:
Arthritis and rheumatism, 60(12), 3572-3581. John Wiley and Sons Inc.
Objective To assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of the CC chemokine receptor CCR1 antagonist MLN3897 in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX). Methods In this phase IIa, proof-of-concept
Autor:
Christian Roux, Ellen Matzkin, Rachelle Eusebio, Claude-Laurent Benhamou, Michael R. McClung, Z. Man, John F. Beary, Artur J. Racewicz, Pierre D. Delmas, David Ernest Burgio, Jose R. Zanchetta, Steven Boonen
Publikováno v:
Bone. 42:36-42
Introduction: Risedronate has been shown to be effective in the treatment of postmenopausal osteoporosis when given orally in daily or weekly doses or on 2 consecutive days per month. This randomized, double-blind, multi-center study was designed to
Autor:
Wojciech P. Olszynski, W. Tlustochowicz, Rachelle Eusebio, Ellen Matzkin, Pierre D. Delmas, Michael R. McClung, Claude-Laurent Benhamou, Jose R. Zanchetta, Z. Man, Robert R. Recker
Publikováno v:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 19(7)
Summary Postmenopausal women with osteoporosis re- ceived 75 mg risedronate on two consecutive days each month or 5 mg daily for 12 months. Changes in bone mineral density and bone turnover markers were similar between treatments. Risedronate 75 mg t
Autor:
Jose R. Zanchetta, Michael R. McClung, Witold Tłustochowicz, Ana Balske, Claude Laurent Benhamou, Rachelle Eusobio, Ellen Matzkin, Z. Man, Robert R. Recker
Publikováno v:
Journal of Clinical Densitometry. 12:393-394
Autor:
Michael R. McClung, Jose R. Zanchetta, Christian Roux, Steven Boonen, Claude-Lauren Benhamou, Z. Man, Rachelle Eusebio, Ellen Matzkin, Artur J. Racewicz
Publikováno v:
Journal of Clinical Densitometry. 12:393
Autor:
Witold Tlustochowicz, Michael R. McClung, Rachelle Eusebio, Claude-Laurent Benhamou, Z. Man, Wojciech P. Olszynski, Robert R. Recker, Ana Balske, Ellen Matzkin, Jose R. Zanchetta, Pierre D. Delmas
Publikováno v:
Calcified Tissue International
This 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate. Postmenopausal women with osteoporosis were randomly assigned to double-blind treatment with risedronate 75 mg on 2 consecutive days each month (2CDM)